Breast Cancer Core Needle Biopsy

Global Breast Cancer Core Needle Biopsy Market to Reach US$1.0 Billion by 2030

The global market for Breast Cancer Core Needle Biopsy estimated at US$843.9 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Ultrasound-based Breast Biopsy, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$569.3 Million by the end of the analysis period. Growth in the MRI-based Breast Biopsy segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$229.9 Million While China is Forecast to Grow at 6.5% CAGR

The Breast Cancer Core Needle Biopsy market in the U.S. is estimated at US$229.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$206.5 Million by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Breast Cancer Core Needle Biopsy Market - Key Trends & Drivers Summarized

Why Is the Demand for Core Needle Biopsy Increasing?

Breast cancer core needle biopsy has emerged as the preferred diagnostic technique due to its minimally invasive nature and high diagnostic accuracy. With breast cancer being one of the leading causes of cancer-related deaths worldwide, early detection remains a critical factor in improving patient outcomes. Core needle biopsy offers a safer and more efficient alternative to surgical biopsies, reducing recovery time and procedural risks. The increasing global burden of breast cancer cases has driven the adoption of advanced biopsy techniques, with healthcare providers emphasizing early and precise diagnosis to ensure effective treatment planning. Additionally, the rising awareness about routine breast cancer screenings, along with government and private sector initiatives promoting diagnostic advancements, has significantly boosted the market demand for breast cancer core needle biopsy procedures.

What Technological Innovations Are Enhancing Biopsy Accuracy?

The market for breast cancer core needle biopsy is witnessing rapid technological advancements that are improving diagnostic precision and patient comfort. Innovations such as vacuum-assisted biopsy systems, real-time ultrasound guidance, and AI-powered image analysis are revolutionizing the biopsy process. These advanced technologies allow for precise tissue extraction, reducing the chances of false negatives and inconclusive results. Additionally, the integration of 3D imaging and digital pathology in biopsy procedures is enhancing the visualization of tumor characteristics, leading to improved detection of early-stage malignancies. As AI and machine learning applications continue to evolve, automated biopsy interpretation tools are further enhancing diagnostic accuracy, reducing variability in pathology reports, and expediting treatment decisions. The continued focus on technological improvements is expected to significantly impact the effectiveness of breast cancer diagnostics.

Which Healthcare Sectors Are Leading the Adoption of Core Needle Biopsy?

The adoption of core needle biopsy is being driven by multiple healthcare segments, including hospitals, diagnostic laboratories, and specialized breast cancer screening centers. Hospitals remain the primary providers of core needle biopsy procedures due to their advanced infrastructure and accessibility to state-of-the-art imaging and pathology services. Diagnostic laboratories are also experiencing increased demand for biopsy services as outpatient diagnostic testing becomes more prevalent. Moreover, mobile screening units and telemedicine platforms are expanding access to early-stage breast cancer diagnostics, particularly in rural and underserved areas. Private healthcare providers and cancer research institutions are also investing heavily in innovative biopsy techniques, ensuring that patients receive accurate and timely diagnoses. With the integration of digital health solutions and remote diagnostic capabilities, the market for breast cancer core needle biopsy is set to expand further.

What Factors Are Driving Market Growth?

The growth in the breast cancer core needle biopsy market is driven by several factors, including rising breast cancer incidence rates, advancements in biopsy technologies, and increasing awareness about early cancer detection. The shift towards minimally invasive procedures has fueled the adoption of core needle biopsy over traditional surgical biopsies, as it offers quicker recovery and reduced patient discomfort. Government-backed screening programs and healthcare reimbursement policies have also contributed to market expansion by making diagnostic procedures more accessible. Additionally, the increasing investment in AI-driven biopsy analysis tools and precision diagnostics is transforming the biopsy landscape, improving detection rates, and streamlining workflow efficiencies. As the demand for high-precision breast cancer diagnostics continues to rise, the breast cancer core needle biopsy market is expected to witness sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Breast Cancer Core Needle Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Ultrasound-based Breast Biopsy, MRI-based Breast Biopsy, Mammography-based (Stereotactic) Breast Biopsy, CT-based Breast Biopsy, Other Technologies); End-Use (Hospitals and Diagnostic Laboratories End-Use, Pharmaceutical and Biotechnology Companies End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Argon Medical Devices, Inc.
• Becton, Dickinson and Company (BD)
• Boston Scientific Corporation
• C.R. Bard, Inc. (BD)
• Cardinal Health, Inc.
• Cook Medical Incorporated
• Danaher Corporation (Leica Biosystems)
• Devicor Medical Products, Inc. (acquired by Leica Biosystems)
• Encapsule Medical Devices LLC
• Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company)
• Fujifilm Holdings Corporation
• Gallini S.r.l.
• Hologic, Inc.
• Intact Medical Corporation
• Leica Biosystems Nussloch GmbH
• Mammotome (a division of Devicor Medical Products, Inc.)
• Medtronic plc
• Olympus Corporation
• SenoRx, Inc. (acquired by C.R. Bard)
• Stryker Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.